Braveheart Bio, Inc. (BRVE)
Last updated: 2026-10-21 20:20:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Braveheart Bio, Inc. (BRVE) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $21.02, with a market capitalization of $1.73B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $17.86 to $32.00. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.73B | |
$20.64 | |
$32.00 | |
$17.86 | |
$20.27 | |
184.27K | |
518.75K | |
-- | |
$32.00 | |
$17.86 | |
-- | |
-- |
Braveheart Bio, Inc. (BRVE) After-Hours Stock Price
Braveheart Bio, Inc. (BRVE) is trading at $21.02 in after-hours trading as of 2026-10-21 19:59:46, up 3.70% ($0.75) from the regular-session close of $20.27.
After-hours trading shows how investors are pricing BRVE after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Braveheart Bio, Inc. (BRVE) 7-Day Stock Price Change
Over the past seven days, Braveheart Bio, Inc. (BRVE) moved from $20.36 to $21.02, representing a gain of 3.24% ($0.66).
The stock traded between $18.00 and $21.48 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 301.25 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
BRVE 52-Week Price Position
Position in Range: 22.3%
BRVE is currently trading at $21.02, placing it 22.3% of the way from its 52-week low of $17.86 to its 52-week high of $32.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Braveheart Bio, Inc. (BRVE)?
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Braveheart Bio, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
How to Buy Braveheart Bio, Inc. (BRVE) Stock on MEXC
Eligible investors can buy real shares of Braveheart Bio, Inc. (BRVE) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Braveheart Bio, Inc. (BRVE) stock price today?
2.Is BRVE stock going up or down today?
3.What is BRVE pre-market price?
4.What is BRVE after-hours price?
5.Is BRVE stock trading now?
6.Where does BRVE sit relative to its 52-week high and low?
7.What sector is Braveheart Bio, Inc. in?
8.What is Braveheart Bio, Inc.'s market capitalization and where is it listed?
9.How is BRVE valued in terms of P/E ratio and EPS?
10.Does Braveheart Bio, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
BRVE Stock Calculator
Estimate the value between BRVE shares and USD.
BRVE Shares to USD
1.00 BRVE shares = 21.02 USD
Calculations are estimates based on the latest available price and are for reference only.



